Navigation
Market Outlook Stock Screener Dividend Calendar Event Calendar Rating of shares Markets News
Try free

Protalix BioTherapeutics

AMEX PLX
$1.14 -0.02 -1.75%
Today share price
Israel
Sector: Healthcare Industry: Biotechnology
Get access
to the rating of Finrange stocks
With this tariff you will be able to use the service without restrictions, all information will be available
Get 7 days free

Rating Finrange

Index: 28 %
Market cap

Market capitalization – refers to the total value of all a company's shares of stock. It is calculated by multiplying the price of a stock by its total number of outstanding shares.

83.17M
EV

Enterprise value is a measure of a company's total value, often used as a more comprehensive alternative to equity market capitalization. Enterprise value includes in its calculation the market capitalization of a company but also short-term and long-term debt as well as any cash on the company's balance sheet.
81.19M
Beta

Beta is one of the most popular indicators of risk is a statistical measure. Analysts use this measure often when they need to determine a stock's risk profile.
2.68
Shares

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company’s insiders.
72.95M
YTD

Year to date (YTD) refers to the period of time beginning the first day of the current calendar year or fiscal year up to the current date. he acronym often modifies concepts such as investment returns and price change.
-35.96 %

Upcoming events Protalix BioTherapeutics

All events
No upcoming events scheduled
Overview Financials Key Metrics Dividends Industry overview Events

Stock chart Protalix BioTherapeutics

Stock analysis Protalix BioTherapeutics

Indicator Company Industry
P/E (LTM)

Shows how many years the investor's investment in the company will pay off with a profit over the last 12 months.

More
10.01 -0.95
P/BV (LTM)

Shows the ratio of the market price of the share to the current book value.

More
2.48 1.94
EV/EBITDA (LTM)

Represents the ratio of the company's value to its pre-tax EBITDA in the last 12 months.

More
6.97 -0.73
Net Debt/EBITDA (LTM)

A company's debt ratio, which indicates how long the company will need to run on cash flow in the past 12 months to pay off its own debt.

More
-0.17 0.24
ROE (LTM)

Shows the efficiency of using the share capital by the company. In other words, ROE shows how much of the company's net profit for the invested capital over the last 12 months.

More
24.76 -87.14

Price change Protalix BioTherapeutics per year

1.21$ 7.02$
Min Max

Summary analysis Protalix BioTherapeutics

Get access
to the rating of Finrange stocks
With this tariff you will be able to use the service without restrictions, all information will be available
Get 7 days free

Shareholder structure Protalix BioTherapeutics

Revenue and net income Protalix BioTherapeutics

All parameters

Stock news Protalix BioTherapeutics

All news
10 May 2023 в 13:30

Protalix BioTherapeutics, Chiesi Global Get FDA Approval for Elfabrio

10 May 2023 в 13:25

Protalix BioTherapeutics, Chiesi Global Get FDA Approval for Elfabrio

4 April 2022 в 19:55

Protalix BioTherapeutics Shares Jump 73% After Positive Trial Results for PRX-102

4 April 2022 в 19:50

Protalix BioTherapeutics Shares Jump 73% After Positive Trial Results for PRX-102

4 April 2022 в 14:21

Protalix BioTherapeutics Sees Positive Trial Results for PRX-102 to Treat Fabry Disease

4 April 2022 в 14:21

Protalix BioTherapeutics Sees Positive Trial Results for PRX-102 to Treat Fabry Disease

About company Protalix BioTherapeutics

Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in Israel, Brazil, rest of Latin America, and internationally. The company offers Elelyso for the treatment of Gaucher disease. Its product pipeline comprises PRX-102, a therapeutic protein candidate, which is in phase III clinical trials for the treatment of Fabry diseases; PRX-110, a proprietary plant cell recombinant form of human deoxyribonuclease I that has completed phase IIa clinical trials for the treatment of cystic fibrosis; PRX-115, a plant cell-expressed recombinant PEGylated Uricase for the treatment of gout; and PRX-119, a plant cell-expressed PEGylated recombinant human DNase I product candidate for the treatment of NETs-related diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz (Fiocruz); and Chiesi Farmaceutici S.p.A. The company was founded in 1993 and is based in Hackensack, New Jersey.
Address:
2 University Plaza, Hackensack, NJ, United States, 07601
Company name: Protalix BioTherapeutics
Issuer ticker: PLX
ISIN: US74365A3095
Country: Israel
Exchange: AMEX
Currency: $
IPO date: 1998-05-15
Sector: Healthcare
Industry: Biotechnology
Site: https://www.protalix.com

On which stock exchange are Protalix BioTherapeutics (PLX) stocks traded?

Protalix BioTherapeutics (PLX) stocks are traded on AMEX.

What is the ticker of Protalix BioTherapeutics stocks (PLX)?

The stock ticker of Protalix BioTherapeutics’s stocks or in other words, the code is PLX. The stocks are currently listed on the AMEX exchange.

In which sector and industry does Protalix BioTherapeutics (PLX) operate?

According to the GICS (Global Industry Classification Standard) classification developed jointly by MSCI and Standard & Poor's, Protalix BioTherapeutics (PLX) belongs to the «Healthcare» sector and the «Biotechnology» industry.

In what currency are Protalix BioTherapeutics (PLX) stocks traded?

Protalix BioTherapeutics (PLX) stocks are traded on the AMEX exchange in dollars.

What is the price of Protalix BioTherapeutics (PLX) stocks today?

The current price of Protalix BioTherapeutics stocks on 06.05.2024 is 1.14 dollars. per share.

What is the dynamics of Protalix BioTherapeutics (PLX) stocks from the beginning of the year?

Protalix BioTherapeutics (PLX) quotes have increased by -37.36% from the beginning of the year up to 1.14 dollars. per 1 stocks.

How much did Protalix BioTherapeutics (PLX) stocks increase in мае 2024?

This month Protalix BioTherapeutics (PLX) quotes have increased by -5.79% to 1.14 dollars. per share.

How much are Protalix BioTherapeutics (PLX) stocks worth?

Today, on October, 06.05.2024 Protalix BioTherapeutics’s (PLX) stocks cost 1.14 dollars..

What is the market capitalization of Protalix BioTherapeutics (PLX)?

Capitalization is the market value of Protalix BioTherapeutics (PLX) is calculated as the number of issued stocks multiplied on the current quotation price. Thus, on 06.05.2024, the market capitalization of Protalix BioTherapeutics (PLX) is estimated at about 83165421 dollars.